Review
Recent Diabetes Issues Affecting the Primary Care Clinician
Abstract
Diabetes accounts for millions of office visits each year to primary care offices in the United States. Successful care of the patient with type 2 diabetes requires not only focus on glucose management but also on comorbidities such as hypertension, dyslipidemia and obesity which are closely linked to microvascular and macrovascular complications. Primary care clinicians must stay abreast of frequently published diabetes literature and new treatments to care for these increasingly complex patients. Metformin and its effect on B12 absorption continues to be an issue encountered by clinicians in daily clinical practice. There has also been recent discussion regarding the increased risk of diabetes with statins; data to date on this issue have been conflicting. Rosiglitazone continues to face public scrutiny and there are now Food and Drug Administration regulations regarding its increased risk of cardiovascular disease. Liraglutide and saxagliptin represent new treatment options for type 2 diabetes, increasing the available options for treating this complex disease. A review of the primary literature involving these topics is provided.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Centers for Disease Control. National Diabetes Fact Sheet. 2007. Available at: http://www.cdc.gov/diabetes/pubs/estimates07.htm#10. Accessed October 1, 2010.
2. Hing E, Hall M, Xu J. National Hospital Ambulatory Medical Care Survey: 2006 Outpatient Department Summary. National Health Statistics Reports. Number 4. August 6, 2008. Available at: http://www.cdc.gov/nchs/data/nhsr/nhsr004.pdf. Accessed November 12, 2010.
3. American Diabetes Association. Standards of Medical Care in Diabetes-2010. Diabetes Care 2010;33(1 suppl):S11-S61.
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203.
5. Glucophage and Glucophage XR [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
6. Tomkin GH, Hadden Dr, Weaver JA, et al. Vitamin-B12 status of patients on long-term metformin therapy. BMJ 1971;2:685-687.
7. Schafer G. Some new aspects on the interaction of hypoglycemia-producing biguanides with biological membranes. Biochem Pharmacol 1976;25:2015-2024.
8. Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12malabsorption induced by metformin. Diabetes Care 2000;23:1227-1231.
9. Pflipsen MC, Oh RC, Saguil A, et al. The prevalence of vitamin B12 deficiency in patients with type 2 diabetes: a cross-sectional study. J Am Board Fam Med 2009;22:528-534.
10. Ting R, Szeto CC, Chan M, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 2006;166:1975-1979.
11. Wulffele MG, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate, and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003;254:455-463.
12. Sahin M, Tutuncu NB, Ertugrul D, et al. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complications 2007;21:118-123.
13. De Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomized placebo controlled trial. BMJ 2010;340:c2181.
14. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
15. Freeman DJ, Norrie J, Sattat N, et al. Pravastatin and the development of diabetes mellitus. Circulation 2001;103:357-362.
16. Keech A, Hague W, Colquhoun D, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care 2003;26:2713-2721.
17. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled study. Lancet 2003;361:2005-2016.
18. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Drugs 2004;64(2 suppl):43-60.
19. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742.
20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471.
21. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135.
22. Home PD, Pocock SJ, Beck-Nielsen H, et al. RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007;357:28-38.
23. Nissen SE, Wolski K. Rosiglitazone revisited. An updated meta-analysis of risk of myocardial infarction and cardiovascular mortality [published online ahead of print, June 28, 2010]. Arch Intern Med2010. DOI:1-.1001/archinternmed.2010.207. Accessed November 5, 2010.
24. Graham DJ, Ouellet-Hellstrom R, MacCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. [published online ahead of print, June 28, 2010]. JAMA 2010 DOI:10.1001/jama.2010.920. Accessed November 5, 2010.
25. US Food and Drug Administration. FDA News Release: FDA significantly restricts access to the diabetes drug Avandia. September 23, 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226975.htm. Accessed November 5, 2010.
26. Charbonnel B, Dormandy J, Erdmann E, et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004;27:1647-1653.
27. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-1554.
28. Elrick H, Stimmler L, Hlad CJ, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-1082.
29. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492-498.
30. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-613.
31. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagonlike peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-613.
32. Drucker DJ, Nauck MA. The incretin system: glucagon- like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
33. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suit-able for once daily administration. J Med Chem 2000;43:1664-1669.
34. Deacon CF, Holst JJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009;26:488-499.
35. Liraglutide [package insert]. Bagsvaerd, Denmark: Novo Nordisk; 2010.
36. Exenatide [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2005.
37. Saxagliptin [package insert]. Wilmington, DE: Bristol-Myers Squibb Company; 2009.
38. Sitagliptin [package insert]. Pavia, Italy: Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc; 2006.
39. Marre M, Shaw J, Brändle M, et al; LEAD-1 SU Study Group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278.
40. Nauck MA, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90.
41. Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481.
42. Zinman B, Gerich J, Buse JB, et al; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met_TZD). Diabetes Care 2009;32:1224-1230.
43. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 Met_SU): a randomized controlled trial. Diabetologia 2009;52:2046-2055.
44. Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, open-label trial (LEAD-6). Lancet 2009;374:39-47.
45. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-2411.
46. DeFronzo RA, Hissa MN, Garber AJ, et al; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655.
47. Hollander P, Li J, Allen E, et al; CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94:4810-4819.
48. Chacra AR, Tan GH, Apanovitch A, et al; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;63:1395-1406.
49. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-777.
